Analyst Reco. Design Therapeutics, Inc.

Equities

DSGN

US25056L1035

Real-time Estimate Cboe BZX Other stock markets 02:59:20 2024-06-05 pm EDT			5-day change	1st Jan Change
4.16 ^USD	+2.46%		+6.62%	+54.91%

May. 08	Design Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 07	Piper Sandler Upgrades Design Therapeutics to Overweight From Neutral	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Piper Sandler Upgrades Design Therapeutics to Overweight From Neutral	May. 07	MT
RBC Cuts Price Target on Design Therapeutics to $4 From $7 Amid Limited Near-Term Clinical Updates, Keeps Sector Perform, Speculative Risk	Nov. 14	MT
Wedbush Trims Design Therapeutics' PT to $5 From $6, Says Waiting for 2024 Strategic Update; Maintains Neutral Rating	Nov. 14	MT
Wedbush Downgrades Design Therapeutics to Neutral From Outperform, Pushes Back DT-216 Launch Timing; Cuts PT to $6 From $19	23-08-15	MT
SVB Downgrades Design Therapeutics to Market Perform From Outperform, Cuts Price Target to $6 From $22	23-08-15	MT
Wedbush Downgrades Design Therapeutics to Neutral From Outperform, Pushes Back DT-216 Launch Timing; Cuts PT to $6 From $19	23-08-15	MT
RBC Downgrades Design Therapeutics to Sector Perform From Outperform, Cuts Price Target to $7 From $23 Amid 'Limited Near-Term Catalysts,' Keeps Speculative Risk	23-08-15	MT
RBC Trims Price Target on Design Therapeutics to $23 From $24, Maintains Outperform Rating, Speculative Risk Qualifier	23-05-10	MT
Wedbush Trims Design Therapeutics' Price Target to $19 From $20, Keeps Outperform Rating	23-05-10	MT
Goldman Sachs Upgrades Design Therapeutics to Neutral From Sell, Price Target is $6	23-05-04	MT
Wedbush Lifts Design Therapeutics' Price Target to $20 From $19, Keeps Outperform Rating	23-03-15	MT
SVB Securities Lowers Price Target on Design Therapeutics to $22 From $30, Maintains Outperform Rating	22-12-09	MT
RBC Cuts Price Target on Design Therapeutics to $24 From $29, Maintains Outperform Rating, Speculative Risk Qualifier	22-12-08	MT
Wedbush Cuts Design Therapeutics' PT to $19 From $26, Pushes Back Expected Market Entry of DT-216 to 2026 After Trial Results; Keeps Outperform Rating	22-12-08	MT
RBC Trims Price Target on Design Therapeutics to $29 From $30, Maintains Outperform, Speculative Risk Rating	22-11-04	MT
Wall Street Set to Open Lower as Mortgage Rates Climb to 16-Year High	22-10-05	MT
US Futures Lower as Mortgage Rates Climb to 16-Year High	22-10-05	MT
Wedbush Adjusts Price Target on Design Therapeutics to $26 From $21, Keeps Outperform Rating	22-08-09	MT
Wedbush Starts Design Therapeutics at Outperform With $21 Price Target	22-06-10	MT
Goldman Sachs Adjusts Design Therapeutics Price Target to $6 From $8, Maintains Sell Rating	22-05-24	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Design Therapeutics, Inc.

Equities

DSGN

US25056L1035

Analyst Reco.

Filters